by University of Basel Credit: Unsplash/CC0 Public Domain Remdesivir was one of the first medications approved for treatment of COVID-19. Clinical studies evaluated its effectiveness, but did not generate conclusive results. A new analysis of the study data shows that a specific group of patients benefits the most from the drug. Since the outbreak of the COVID-19...
Credit: Unsplash/CC0 Public Domain A three-day course of remdesivir results in a lower risk for hospitalization or death compered with placebo among nonhospitalized patients at high risk for COVID-19 progression, according to a study published online Dec. 22 in the New England Journal of Medicine. Robert L. Gottlieb, M.D., Ph.D., from the Baylor University Medical Center...
INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation. In an early benefit assessment, the German Institute for Quality and...
FEBRUARY 1ST, 2021 POSTED BY MARC AIRHART-TEXAS Remdesivir is the only treatment of its kind currently approved in the US for the coronavirus. The findings could lead to more effective antiviral treatments. Remdesivir targets a part of the coronavirus that allows it to make copies of itself and spread through the body. For the first...
by Emily Ayshford, University of Chicago SARS-CoV-2 (shown here in an electron microscopy image). Credit: National Institute of Allergy and Infectious Diseases, NIH In the treatment of SARS-CoV-2, the virus that causes COVID-19, antiviral drug remdesivir has emerged as a promising candidate. Remdesivir works by disrupting the virus’s ability to replicate, but its exact mechanism has remained...
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. The results suggest plitidepsin should be further evaluated...
by Max Planck Society The Covid-19 drug remdesivir (purple) is incorporated into the new RNA chain during the copying process and suppresses the duplication of the coronavirus genome. Credit: Hauke Hillen, Goran Kokic, and Patrick Cramer / Max Planck Institute for Biophysical Chemistry Remdesivir is the first drug against COVID-19 to be conditionally approved in Europe...
UNIVERSITY OF CINCINNATI IMAGE: Bingfang Yan is a professor at the University of Cincinnati’s James L. Winkle College of Pharmacy. Yan’s UC laboratory studies how drugs are metabolized in the body to see if certain people should or should not use the drug or use it at a different dose. He has, for decades, been...
President Donald Trump and Food and Drug Administration Commissioner Stephen Hahn (right) met with Daniel O’Day (left), CEO of Gilead Sciences, when remdesivir received an emergency use authorization in May. October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an...
